Mersana Therapeutics, Inc. Uncategorized Contracts & Agreements
14 Contracts & Agreements
- Offer Letter, dated (Filed With SEC on February 28, 2024)
- Letter Agreement (Filed With SEC on November 7, 2023)
- Offer Letter, dated September 5, 2023, by and between Mersana Therapeutics, Inc. and Martin Huber (Filed With SEC on November 7, 2023)
- Amendment No (Filed With SEC on November 7, 2023)
- Agreement Regarding LICR Technology, dated July 9, 2015, by and between Ludwig Institute for Cancer Research, Recepta Biopharma S.A. and Mersana Therapeutics, Inc (Filed With SEC on May 9, 2023)
- Description of Securities (Filed With SEC on February 28, 2023)
- Offer Letter, dated June 15, 2021, between the Company and Tushar Misra (Filed With SEC on May 9, 2022)
- Offer Letter, dated March 5, 2021, between the Company and Alejandra Carvajal (Filed With SEC on May 9, 2022)
- Amended and Restated Offer Letter, by and between Mersana Therapeutics, Inc. and Michael Kaufman, dated March 8, 2017 (Filed With SEC on May 10, 2021)
- Offer Letter, by and between Mersana Therapeutics, Inc. and Arvin Yang, dated November 5, 2020 (Filed With SEC on May 10, 2021)
- Offer Letter, by and between Mersana Therapeutics, Inc. and Brian DeSchuytner, dated June 10, 2019 (Filed With SEC on May 8, 2020)
- Offer Letter, by and between Mersana Therapeutics, Inc. and Dirk Huebner, dated November 5, 2018 (Filed With SEC on May 8, 2020)
- Offer Letter, by and between Mersana Therapeutics, Inc. and David Spellman, dated December 18, 2017 (Filed With SEC on May 9, 2019)
- CONFIDENTIAL (Filed With SEC on June 1, 2017)
